ProQuad [Measles, Mumps, Rubella, and Varicella (Oka/Merck) Virus Vaccine Live]

Published Online: Thursday, December 1, 2005

Merck & Co Inc (Whitehouse Station, NJ) recently received FDA approval for the combination vaccine ProQuad for simultaneous vaccination against measles, mumps, rubella (German measles), and varicella (chickenpox) in children 12 months to 12 years of age. The product also may be used in this patient group if a second dose of measles, mumps, and rubella vaccine is to be administered. Patients should receive a 0.5-mL single dose of ProQuad subcutaneously. At least 1 month should elapse between a dose of a measles-containing vaccine and a dose of ProQuad. If a second dose of varicella-containing vaccine is required, at least 3 months should elapse. For more information, visit

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues